南方港股医药行业混合发起(QDII)A(019415)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-5,431,344.90 |
9,720,811.27 |
8,227,070.71 |
-443,422.92 |
| 利息合计 |
8,280.84 |
14,443.56 |
4,131.65 |
1,292.41 |
| 其中:存款利息收入 |
8,280.84 |
14,443.56 |
4,131.65 |
1,292.41 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-6,373,505.86 |
7,381,009.51 |
2,582,719.45 |
-670,500.65 |
| 其中:股票投资收益 |
-7,028,253.58 |
7,000,729.66 |
2,358,978.86 |
-776,683.81 |
| 基金投资收益 |
570,281.25 |
49,113.26 |
50,956.57 |
-33,318.15 |
| 债券投资收益 |
- |
- |
- |
2,622.46 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
84,466.47 |
331,166.59 |
172,784.02 |
136,878.85 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
997,315.76 |
2,003,520.32 |
5,552,867.91 |
235,259.01 |
| 其他收入 |
84,611.25 |
520,528.91 |
145,401.79 |
13,404.82 |
| 费用 |
469,359.56 |
833,069.29 |
185,543.98 |
151,639.92 |
| 管理人报酬 |
304,212.42 |
540,987.83 |
135,040.43 |
120,705.51 |
| 基金托管费 |
50,702.04 |
90,164.61 |
22,506.72 |
20,117.60 |
| 销售服务费 |
56,481.41 |
101,323.08 |
22,528.61 |
2,816.81 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
55,898.69 |
100,389.94 |
5,264.39 |
8,000.00 |
| 利润总额 |
-5,900,704.46 |
8,887,741.98 |
8,041,526.73 |
-595,062.84 |